IBDEI115 ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1302,0)
 ;;=KNEE^10^86
 ;;^UTILITY(U,$J,358.4,1303,0)
 ;;=OTHER ^12^86
 ;;^UTILITY(U,$J,358.4,1304,0)
 ;;=PAIN^13^86
 ;;^UTILITY(U,$J,358.4,1305,0)
 ;;=PELVIS/HIP^14^86
 ;;^UTILITY(U,$J,358.4,1306,0)
 ;;=SHOULDER^17^86
 ;;^UTILITY(U,$J,358.4,1307,0)
 ;;=TIBIA/FIBULA^19^86
 ;;^UTILITY(U,$J,358.4,1308,0)
 ;;=WRIST^20^86
 ;;^UTILITY(U,$J,358.4,1309,0)
 ;;=AMPUTATION STATUS^2^86
 ;;^UTILITY(U,$J,358.4,1310,0)
 ;;=SECONDARY DX ONLY^15^86
 ;;^UTILITY(U,$J,358.4,1311,0)
 ;;=AFTERCARE/POST-OP/JOINT/SUTURE/DRESSING^1^86
 ;;^UTILITY(U,$J,358.4,1312,0)
 ;;=SPINE^18^86
 ;;^UTILITY(U,$J,358.4,1313,0)
 ;;=ESTABLISHED PATIENT^1^87
 ;;^UTILITY(U,$J,358.4,1314,0)
 ;;=CONSULTATION-CLINICIAN^2^87
 ;;^UTILITY(U,$J,358.4,1315,0)
 ;;=NEW PATIENT^3^87
 ;;^UTILITY(U,$J,358.4,1316,0)
 ;;=NEUROLYSIS^2^88
 ;;^UTILITY(U,$J,358.4,1317,0)
 ;;=NEUROSTIMULATORS^3^88
 ;;^UTILITY(U,$J,358.4,1318,0)
 ;;=OTHER PROCEDURES^4^88
 ;;^UTILITY(U,$J,358.4,1319,0)
 ;;=SPINAL PROCEDURES/NERVE BLOCKS^6^88
 ;;^UTILITY(U,$J,358.4,1320,0)
 ;;=TEAM CONFERENCE^7^88
 ;;^UTILITY(U,$J,358.4,1321,0)
 ;;=PROLONGED SERVICES^5^88
 ;;^UTILITY(U,$J,358.4,1322,0)
 ;;=ACUPUNCTURE^1^88
 ;;^UTILITY(U,$J,358.4,1323,0)
 ;;=ABDOMINAL PAIN^1^89
 ;;^UTILITY(U,$J,358.4,1324,0)
 ;;=CARDIAC^2^89
 ;;^UTILITY(U,$J,358.4,1325,0)
 ;;=DIGESTIVE SYSTEM DISEASES^3^89
 ;;^UTILITY(U,$J,358.4,1326,0)
 ;;=NERVOUS SYSTEM DISEASES^7^89
 ;;^UTILITY(U,$J,358.4,1327,0)
 ;;=GENERAL SIGNS & SYMPTOMS^4^89
 ;;^UTILITY(U,$J,358.4,1328,0)
 ;;=INFECTIOUS DISEASES^5^89
 ;;^UTILITY(U,$J,358.4,1329,0)
 ;;=MALIGNANT NEOPLASMS^6^89
 ;;^UTILITY(U,$J,358.4,1330,0)
 ;;=OTHER^8^89
 ;;^UTILITY(U,$J,358.4,1331,0)
 ;;=PRE/POST SURGERY^9^89
 ;;^UTILITY(U,$J,358.4,1332,0)
 ;;=RESPIRATORY^10^89
 ;;^UTILITY(U,$J,358.4,1333,0)
 ;;=PEER SERVICES^1^90
 ;;^UTILITY(U,$J,358.4,1334,0)
 ;;=ABUSE,NEGLECT, & VIOLENCE^1^91
 ;;^UTILITY(U,$J,358.4,1335,0)
 ;;=ANXIETY DISORDERS^2^91
 ;;^UTILITY(U,$J,358.4,1336,0)
 ;;=BIPOLAR DISORDERS^3^91
 ;;^UTILITY(U,$J,358.4,1337,0)
 ;;=NEUROCOGNITIVE DISORDERS^17^91
 ;;^UTILITY(U,$J,358.4,1338,0)
 ;;=DEPRESSIVE DISORDERS^7^91
 ;;^UTILITY(U,$J,358.4,1339,0)
 ;;=DISSOCIATIVE DISORDERS ^9^91
 ;;^UTILITY(U,$J,358.4,1340,0)
 ;;=FEEDING & EATING DISORDERS^12^91
 ;;^UTILITY(U,$J,358.4,1341,0)
 ;;=EDUCATIONAL/OCCUPATIONAL PROBLEMS^10^91
 ;;^UTILITY(U,$J,358.4,1342,0)
 ;;=GENDER DYSPHORIA^14^91
 ;;^UTILITY(U,$J,358.4,1343,0)
 ;;=HOUSING/ECONOMIC PROBLEMS^15^91
 ;;^UTILITY(U,$J,358.4,1344,0)
 ;;=MEDICATION-INDUCED MOVEMENT DISORDERS^16^91
 ;;^UTILITY(U,$J,358.4,1345,0)
 ;;=OBSESSIVE-COMPULSIVE & RELATED DISORDERS^19^91
 ;;^UTILITY(U,$J,358.4,1346,0)
 ;;=PERSONAL HX & CURRENT CIRCUMSTANCES^22^91
 ;;^UTILITY(U,$J,358.4,1347,0)
 ;;=COUNSELING/MEDICAL ADVICE^5^91
 ;;^UTILITY(U,$J,358.4,1348,0)
 ;;=SOCIAL ENVIRONMENT PROBLEMS^29^91
 ;;^UTILITY(U,$J,358.4,1349,0)
 ;;=PARAPHILIC DISORDERS^21^91
 ;;^UTILITY(U,$J,358.4,1350,0)
 ;;=PERSONALITY DISORDERS^23^91
 ;;^UTILITY(U,$J,358.4,1351,0)
 ;;=CRIME/LEGAL SYSTEM PROBLEMS^6^91
 ;;^UTILITY(U,$J,358.4,1352,0)
 ;;=PSYCHOSOCIAL/PERSONAL/ENVIRONMENTAL^24^91
 ;;^UTILITY(U,$J,358.4,1353,0)
 ;;=RELATIONAL PROBLEMS^25^91
 ;;^UTILITY(U,$J,358.4,1354,0)
 ;;=SCHIZOPHRENIA/OTH PSYCHOTIC DISORDERS^26^91
 ;;^UTILITY(U,$J,358.4,1355,0)
 ;;=SEXUAL DYSFUNCTIONS^27^91
 ;;^UTILITY(U,$J,358.4,1356,0)
 ;;=SLEEP-WAKE DISORDERS^28^91
 ;;^UTILITY(U,$J,358.4,1357,0)
 ;;=SUBSTANCE USE DISORDER-ALCOHOL^31^91
 ;;^UTILITY(U,$J,358.4,1358,0)
 ;;=SUBSTANCE USE DISORDER-CANNABIS^33^91
 ;;^UTILITY(U,$J,358.4,1359,0)
 ;;=SUBSTANCE USE DISORDER-HALLUCINOGEN^34^91
 ;;^UTILITY(U,$J,358.4,1360,0)
 ;;=SUBSTANCE USE DISORDER-OPIOID^36^91
 ;;^UTILITY(U,$J,358.4,1361,0)
 ;;=SUBSTANCE USE DISORDER-SEDATIVE/HYPNOTIC^37^91
 ;;^UTILITY(U,$J,358.4,1362,0)
 ;;=SUBSTANCE USE DISORDER-TOBACCO^39^91
 ;;^UTILITY(U,$J,358.4,1363,0)
 ;;=TRAUMA/STRESSOR-RELATED DISORDERS^42^91
 ;;^UTILITY(U,$J,358.4,1364,0)
 ;;=SUBSTANCE USE DISORDER-INHALANT^35^91
 ;;^UTILITY(U,$J,358.4,1365,0)
 ;;=CLINICAL RESEARCH PROGRAM^4^91
 ;;^UTILITY(U,$J,358.4,1366,0)
 ;;=SOMATIC SYMPTOM & RELATED DISORDERS^30^91
 ;;^UTILITY(U,$J,358.4,1367,0)
 ;;=DISRUPTIVE,IMPULSE-CONTROL DISORDERS^8^91
 ;;^UTILITY(U,$J,358.4,1368,0)
 ;;=ELIMINATION DISORDERS^11^91
 ;;^UTILITY(U,$J,358.4,1369,0)
 ;;=GAMBLING DISORDER^13^91
 ;;^UTILITY(U,$J,358.4,1370,0)
 ;;=OTHER MENTAL DISORDERS^20^91
 ;;^UTILITY(U,$J,358.4,1371,0)
 ;;=NEURODEVELOPMENTAL DISORDERS^18^91
 ;;^UTILITY(U,$J,358.4,1372,0)
 ;;=SUBSTANCE USE DISORDER-CAFFEINE^32^91
 ;;^UTILITY(U,$J,358.4,1373,0)
 ;;=SUICIDAL IDEATIONS^41^91
 ;;^UTILITY(U,$J,358.4,1374,0)
 ;;=SUBSTANCE USE DISORDER-UNKNOWN SUBSTANCE^40^91
 ;;^UTILITY(U,$J,358.4,1375,0)
 ;;=SUBSTANCE USE DISORDER-STIMULANTS^38^91
 ;;^UTILITY(U,$J,358.4,1376,0)
 ;;=UNDERDOSING OF MEDICATION REGIMEN^43^91
 ;;^UTILITY(U,$J,358.4,1377,0)
 ;;=INPT H&P-NEW ADMISSION^4^92
 ;;^UTILITY(U,$J,358.4,1378,0)
 ;;=INITIAL OBSERVATION^1^92
 ;;^UTILITY(U,$J,358.4,1379,0)
 ;;=INPT CONSULTATIONS^5^92
 ;;^UTILITY(U,$J,358.4,1380,0)
 ;;=INPT-ESTABLISHED PATIENT CARE^6^92
 ;;^UTILITY(U,$J,358.4,1381,0)
 ;;=INPT DISCHARGES^7^92
 ;;^UTILITY(U,$J,358.4,1382,0)
 ;;=SUBSEQUENT OBSERVATION^2^92
 ;;^UTILITY(U,$J,358.4,1383,0)
 ;;=OBSERVATION DISCHARGE^3^92
 ;;^UTILITY(U,$J,358.4,1384,0)
 ;;=INJECTIONS/DRUGS^7^93
 ;;^UTILITY(U,$J,358.4,1385,0)
 ;;=WOUND CARE^15^93
 ;;^UTILITY(U,$J,358.4,1386,0)
 ;;=MD PROCEDURES^1^93
 ;;^UTILITY(U,$J,358.4,1387,0)
 ;;=MUSCLE NERVE TESTS^9^93
 ;;^UTILITY(U,$J,358.4,1388,0)
 ;;=TEAM CONFERENCE^12^93
 ;;^UTILITY(U,$J,358.4,1389,0)
 ;;=ACUPUNCTURE^2^93
 ;;^UTILITY(U,$J,358.4,1390,0)
 ;;=CHEMODENERVATION^6^93
 ;;^UTILITY(U,$J,358.4,1391,0)
 ;;=OTHER^10^93
 ;;^UTILITY(U,$J,358.4,1392,0)
 ;;=BACLOFEN PUMP^3^93
 ;;^UTILITY(U,$J,358.4,1393,0)
 ;;=BOTOX^4^93
 ;;^UTILITY(U,$J,358.4,1394,0)
 ;;=CARPAL TUNNEL INJECTION^5^93
 ;;^UTILITY(U,$J,358.4,1395,0)
 ;;=JNT BURSA INJ W/ US^8^93
 ;;^UTILITY(U,$J,358.4,1396,0)
 ;;=TRIGGER POINT INJECTION^13^93
 ;;^UTILITY(U,$J,358.4,1397,0)
 ;;=ULTRASOUND^14^93
 ;;^UTILITY(U,$J,358.4,1398,0)
 ;;=PROLONGED SERVICE^11^93
 ;;^UTILITY(U,$J,358.4,1399,0)
 ;;=INITIAL EVAL FOR TBI^12^94
 ;;^UTILITY(U,$J,358.4,1400,0)
 ;;=INJURY/TRAUMA (SEQUELA)^13^94
 ;;^UTILITY(U,$J,358.4,1401,0)
 ;;=LATE EFFECTS OF CVA^14^94
 ;;^UTILITY(U,$J,358.4,1402,0)
 ;;=AMPUTATION STATUS^1^94
 ;;^UTILITY(U,$J,358.4,1403,0)
 ;;=AUDITORY^3^94
 ;;^UTILITY(U,$J,358.4,1404,0)
 ;;=BACK DIAGNOSIS^4^94
 ;;^UTILITY(U,$J,358.4,1405,0)
 ;;=BRAIN DISORDERS^5^94
 ;;^UTILITY(U,$J,358.4,1406,0)
 ;;=CARDIOPULMONARY^6^94
 ;;^UTILITY(U,$J,358.4,1407,0)
 ;;=COGNITION^7^94
 ;;^UTILITY(U,$J,358.4,1408,0)
 ;;=COMPLICATION DUE TO^8^94
 ;;^UTILITY(U,$J,358.4,1409,0)
 ;;=ARTHRITIS^2^94
 ;;^UTILITY(U,$J,358.4,1410,0)
 ;;=FRACTURES^10^94
 ;;^UTILITY(U,$J,358.4,1411,0)
 ;;=MENTAL DISORDERS^15^94
 ;;^UTILITY(U,$J,358.4,1412,0)
 ;;=MUSCULOSKELETAL/CONNECTIV^16^94
 ;;^UTILITY(U,$J,358.4,1413,0)
 ;;=GENERAL SIGNS/SYMPTOMS^11^94
 ;;^UTILITY(U,$J,358.4,1414,0)
 ;;=POST JOINT REPLACEMENT^17^94
 ;;^UTILITY(U,$J,358.4,1415,0)
 ;;=RHEUMATOID^19^94
 ;;^UTILITY(U,$J,358.4,1416,0)
 ;;=PSYCHIATRIC-PSYCHOSOC-EMO^18^94
 ;;^UTILITY(U,$J,358.4,1417,0)
 ;;=SPEECH AND LANGUAGE^20^94
 ;;^UTILITY(U,$J,358.4,1418,0)
 ;;=FITTING/ADJUSTMENT/AFTERCARE^9^94
 ;;^UTILITY(U,$J,358.4,1470,0)
 ;;=NEW PATIENT^2^98
 ;;^UTILITY(U,$J,358.4,1471,0)
 ;;=ESTABLISHED PATIENT^1^98
 ;;^UTILITY(U,$J,358.4,1472,0)
 ;;=CONSULTATIONS^3^98
 ;;^UTILITY(U,$J,358.4,1473,0)
 ;;=IMMUNIZATION^7^99
 ;;^UTILITY(U,$J,358.4,1474,0)
 ;;=INJECTION^8^99
 ;;^UTILITY(U,$J,358.4,1475,0)
 ;;=SKIN TEST^17^99
 ;;^UTILITY(U,$J,358.4,1476,0)
 ;;=NURSING PROCEDURES^10^99
 ;;^UTILITY(U,$J,358.4,1477,0)
 ;;=MINOR PROCEDURES^9^99
 ;;^UTILITY(U,$J,358.4,1478,0)
 ;;=SPLINTS^18^99
 ;;^UTILITY(U,$J,358.4,1479,0)
 ;;=EDUCATION/TRAINING^3^99
 ;;^UTILITY(U,$J,358.4,1480,0)
 ;;=ALLERGY SHOTS^1^99
 ;;^UTILITY(U,$J,358.4,1481,0)
 ;;=EKG^4^99
 ;;^UTILITY(U,$J,358.4,1482,0)
 ;;=BEHAVIORAL CHANGE INTERVENTION^2^99
 ;;^UTILITY(U,$J,358.4,1483,0)
 ;;=OTH PREVENTIVE MEDICINE SVCS^11^99
 ;;^UTILITY(U,$J,358.4,1484,0)
 ;;=GYN PROCEDURES^5^99
 ;;^UTILITY(U,$J,358.4,1485,0)
 ;;=PREVENTIVE MED-EST PT^13^99
 ;;^UTILITY(U,$J,358.4,1486,0)
 ;;=PREVENTIVE MED-NEW PT^14^99
 ;;^UTILITY(U,$J,358.4,1487,0)
 ;;=RISK FACTOR REDUCTION^16^99
 ;;^UTILITY(U,$J,358.4,1488,0)
 ;;=PREVENTIVE GROUP COUNSELING^12^99
 ;;^UTILITY(U,$J,358.4,1489,0)
 ;;=PROLONGED SERVICE^15^99
 ;;^UTILITY(U,$J,358.4,1490,0)
 ;;=IMMUNIZATION ADMINISTRATION^6^99
 ;;^UTILITY(U,$J,358.4,1491,0)
 ;;=PC COMMON DIAGNOSES^1^100
 ;;^UTILITY(U,$J,358.4,1492,0)
 ;;=ADMINISTRATIVE TOPICS^2^100
 ;;^UTILITY(U,$J,358.4,1493,0)
 ;;=ANGINA^3^100
 ;;^UTILITY(U,$J,358.4,1494,0)
 ;;=ATHEROSCLEROSIS^4^100
 ;;^UTILITY(U,$J,358.4,1495,0)
 ;;=CARDIOVASCULAR^5^100
 ;;^UTILITY(U,$J,358.4,1496,0)
 ;;=DERMATOLOGY^9^100
 ;;^UTILITY(U,$J,358.4,1497,0)
 ;;=EAR DISORDERS^10^100
 ;;^UTILITY(U,$J,358.4,1498,0)
 ;;=EENT^11^100
 ;;^UTILITY(U,$J,358.4,1499,0)
 ;;=ENDOCRINE/METABOLIC^12^100
 ;;^UTILITY(U,$J,358.4,1500,0)
 ;;=EYE DISORDERS^13^100
 ;;^UTILITY(U,$J,358.4,1501,0)
 ;;=EYE INJURY^14^100
 ;;^UTILITY(U,$J,358.4,1502,0)
 ;;=GASTROENTEROLOGY^15^100
 ;;^UTILITY(U,$J,358.4,1503,0)
 ;;=GU/RENAL^16^100
 ;;^UTILITY(U,$J,358.4,1504,0)
 ;;=HEADACHE^17^100
 ;;^UTILITY(U,$J,358.4,1505,0)
 ;;=HEART FAILURE^18^100
 ;;^UTILITY(U,$J,358.4,1506,0)
 ;;=HEART VALVE DISEASE^19^100
 ;;^UTILITY(U,$J,358.4,1507,0)
 ;;=HEMATOLOGY/ONCOLOGY^20^100
 ;;^UTILITY(U,$J,358.4,1508,0)
 ;;=HISTORY OF ILLNESS^21^100
 ;;^UTILITY(U,$J,358.4,1509,0)
 ;;=INFECTIOUS DISEASE^22^100
 ;;^UTILITY(U,$J,358.4,1510,0)
 ;;=LIVER DISEASE^23^100
 ;;^UTILITY(U,$J,358.4,1511,0)
 ;;=MENTAL HEALTH^25^100
 ;;^UTILITY(U,$J,358.4,1512,0)
 ;;=MOVEMENT DISORDERS^26^100
 ;;^UTILITY(U,$J,358.4,1513,0)
 ;;=MUSCULOSKELETAL^27^100
 ;;^UTILITY(U,$J,358.4,1514,0)
 ;;=NEUROLOGY^28^100
